Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a rare occurrence of injection site reactions in a 77-year-old woman with eosinophilic fasciitis using subcutaneous methotrexate, marking the first documented instance in this patient population.

This review discusses the use of recombinant cytokines as therapeutic agents in clinical settings and describes the range of cutaneous complications associated with their use, including both minor and severe skin reactions.

In this study, 19.6% of COVID-19 vaccine recipients reported post-vaccination mucocutaneous effects, mostly mild and self-limiting; the reactions were similarly frequent for Covishield and Covaxin.

In this study, 93% of patients with inflammatory arthritis remained on the adalimumab biosimilar ABP 501 for 24 weeks after switching from the originator, with some switching back due to adverse reactions or reduced effectiveness.

In these two clinical trials, DS-2325a, a KLK5 inhibitor, was found to be generally safe and well tolerated in healthy volunteers, with mild and non-serious adverse events, suggesting its potential for further development as a treatment for Netherton Syndrome.

In this retrospective cohort study, 53.8% of adult rosacea patients who started CGRP monoclonal antibodies for migraines experienced improvement in papules/pustules and erythema/flushing, although moderate adverse events were noted, suggesting these antibodies may benefit rosacea symptoms.

This review details the adverse effects and drug interactions of biologic agents used in rheumatoid disease treatment, highlighting their significant side effect profile without reporting new clinical findings.

This article discusses the benefits of follicular unit transplantation for male hair restoration, highlighting its ability to achieve natural-looking results with minimal recovery time and low risk of complications, and reports no new clinical results.

This study found that VYC-15L (Juvéderm Volbella XC) was safe and effective for enhancing lip and perioral areas, achieving higher lip fullness improvement and fewer severe injection site reactions compared to NASHA, with effects lasting up to one year.

This article highlights adverse skin reactions due to injectable therapies for MS, noting that while generally mild, some cases can progress to serious lesions requiring medical intervention.

This study found that GLP-1 receptor agonists show potential for improving psoriasis and hidradenitis suppurativa by reducing inflammation and lesion severity, but they also pose dermatological risks such as alopecia and injection site reactions.

This study reports that comorbidities and anti-androgen therapy were associated with lower SARS-CoV-2 vaccination rates among patients with androgenetic alopecia, emphasizing the need to promote vaccination within this group.

In this study, clinically used preoperative skin preparations with povidone iodine and chlorhexidine gluconate did not meet FDA log-reduction standards for bacterial bioburden in a porcine model, suggesting persistent infection risks.

In this study, pegylated interferon alfa-2b injections led to local cutaneous reactions, including cutaneous necrosis, in patients with hepatitis C and chronic myelocytic leukemia, requiring dose modifications or treatment withdrawal in some cases.

This case report highlights a patient who developed cutaneous sarcoidal lesions at the site of platelet-rich plasma injections after COVID-19 infection and vaccination, suggesting possible immune system involvement.

This review outlines the various adverse reactions to biologic therapies in Allergy/Immunology, emphasizing the clinical and management challenges due to overlapping reaction phenotypes and the need for more refined diagnostic and management strategies.

This study found that gelatin-resorcinol-formaldehyde caused peritoneal lesions and hair loss in rats and mice, indicating it is unsuitable for tubal occlusion and emphasizing the need for testing in multiple species before using compounds in humans.

In this study, peginterferon alfa-2b plus ribavirin therapy in hepatitis C patients was associated with serious adverse drug reactions in 20% of cases, highlighting differences from clinical trial findings.

This study reported that dupilumab, an FDA-approved biologic, is a safe and effective first-line systemic treatment for children with moderate-to-severe atopic dermatitis, showing sustained skin improvement and itch reduction, with injection site reactions and conjunctivitis as potential side effects.

In this study analyzing FDA data, researchers found that tralokinumab was associated with higher reports of conjunctivitis and keratitis compared to dupilumab, while dupilumab had more frequent injection site reactions, highlighting potential risks for clinical monitoring in atopic dermatitis treatments.

This review discusses various skin reactions after SARS-CoV-2 infection and COVID-19 vaccination, noting a higher incidence with mRNA vaccines than adenovirus vector vaccines, and reports no new clinical results.

This study describes a new two-step method for effectively removing hair particles from split-thickness skin grafts from the scalp, potentially preventing foreign-body reactions at recipient sites.

This study's meta-analysis found that COVID-19 vaccines are effective and safe for children, with inactivated vaccines showing the highest effectiveness and causing less injection site pain compared to attenuated vaccines.

This study found that a single intradermal injection of Hair Stimulating Complex significantly improved hair growth in men with androgenetic alopecia compared to placebo.

This case report illustrates that fibrosing alopecia in a pattern distribution may be misdiagnosed as androgenetic alopecia due to similar hair loss patterns, but distinctive trichoscopic and histopathologic features help differentiate it.

In this study conducted at Baqiyatullah Hospital, it was found that interferon beta (IFNβ) treatment in multiple sclerosis patients commonly led to skin complications, with injection site erythema being most frequent, and also increased hair loss severity.

This study identified both known and additional potential adverse reactions to tralokinumab in real-world use for atopic dermatitis, highlighting the importance of monitoring adverse events, especially in the first month of treatment.

This article discusses the side effects of interferon beta therapy for MS, including flu-like symptoms and autoimmune reactions, and provides guidance on their management but does not report new clinical findings.

This study confirmed known adverse events and identified new ones related to ixekizumab, offering preliminary safety insights for its clinical use, but noted limitations such as potential underreporting and confounding factors in the spontaneous adverse event reporting systems.

This review discusses the dermatologic side effects and potential therapeutic benefits of GLP-1 receptor agonists, such as facial fat loss and wound healing, emphasizing the need for further research.